SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp XCN price spike is driving attention, with traders highlighting a large candle and rapid gains despite no clear new catalyst. The community is split between buyers anticipating a breakout and skeptics calling the move another short-lived pump-and-dump, while some attribute price swings to Bitcoin and broader crypto-market conditions.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crudes rally amid escalating Middle East tensions and supply-disruption fears is driving attention to UCO, with traders focused on shipping risks and tight oil markets. Many are bullish on oil exposure, while others warn of a sharp run-up and possible pullback; the Russian diesel supply deal also raises debate about whether added supply could ease prices.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee has joined Irth Capitals take-private bid have revived buyout speculation. Traders are hopeful but divided over whether a deal will close, with frustration at the boards silence and continued concerns about weak sales and the suspended dividend.

TOSHI

TOSHI is drawing attention around increased trading activity and repeated attempts to break a stubborn resistance level, with traders speculating about a breakout or short squeeze. Bulls are buying dips and expecting a rebound, while skeptics point to repeated rejections, weak price action, and broader crypto-market softness.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens IMDELLTRAIMFINZI combination showed a substantial survival benefit in a Phase 3 trial for first-line extensive-stage small-cell lung cancer, drawing attention to the drugs potential expansion and growth prospects. Traders are broadly positive on the data, while some debate how much it could add commercially alongside established products such as Repatha.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on Dow and broader-market volatility, with traders weighing rallies and the Dows relative strength against concerns about rising Treasury yields, inflation and Fed policy, and Iran-related oil risks. Views are split between bullish calls for continued gains and warnings of further declines; no single company-specific catalyst dominates.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIBs extended sideways trading and repeated consolidation near recent levels dominate the conversation, with traders sharing technical levels and debating whether to buy dips or expect another meme-coin rally. Optimistic holders are accumulating and waiting for a breakout, while others are frustrated by the lack of momentum and question the tokens utility and prospects.

Anthropic

Anthropics reported preparations for a potential mega-IPO are driving attention, with traders focused on the timing, filing and possible valuation. The community is divided between enthusiasm for rapid revenue growth and skepticism about the companys heavy infrastructure commitments, losses and intensifying AI competition.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyagers proposed convertible-notes financing has fueled concerns about dilution and added pressure to a stock many traders say has lagged other space names. The community is split between frustrated holders blaming management and financing decisions, and buyers who see the pullback as an opportunity based on the companys longer-term space and defense prospects.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and suspension of its dividend have sparked heavy selling, with management citing recession-level appliance demand and the Iran war. Traders are sharply divided between fears of debt trouble and management failure, including bankruptcy speculation, and bargain hunters betting the selloff has gone too far.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines...

What Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R. Cruz Outlines...

Robbins LLP Urges AVXL Stockholders Who Lost Money Investing in Anavex Life Sciences Corp. to Contact the Firm for Information About Leading the Class Action

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action...

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.   New York, NY – October 21, 2026 – Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the […]
The post Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market appeared first on Financial News Media.

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law FirmPR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026...

AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 Contact Kirby McInerney LLP to Discuss Your Rights

If you have suffered a loss on your Anavex Life Sciences Corp. (Anavex or the Company) (NASDAQ: AVXL) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class...

Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AVXL

Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AVXL Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AVXLPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026...

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit with SBS Law

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit with SBS Law AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 12, 2026LOS ANGELES, Oct. 12, 2026 /PRNewswire/ -- Schall...

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Anavex stated it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.</li><li>The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises office to move forward with marketing authorization preparations.</li><li>This comes two days after Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage.</li></ul>Anavex Life Sciences Corp. (AVXL) shares tanked more than 33% in Wednesday’s opening trade after the company announced that it has withdrawn its marketing authorization application for its Alzheimer’s drug, blarcamesine, in the European Union.Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.This comes two days after Anavex&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-soars-anavex-alzheimers-drug-blarcamesine-slows-brain-shrinkage/cZ3mhyrRI0F">reported</a> new data about blarcamesine, suggesting a slowdown in brain shrinkage.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AVXL">Anavex Life Sciences</a> trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Did Anavex Withdraw Application?</h2>Anavex stated that it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises (SMEs) office to move forward with marketing authorization preparations.“Anavex now has to take note of the differing assessment of the CHMP at the EMA and will consider the constructive feedback received from the CHMP and focus on gathering additional data and conducting further analyses to address the points raised by the CHMP,” the company stated.<h2 class="st-heading-2">New Blarcamesine Trial Data Suggests Slowdown In Brain Shrinkage</h2>Earlier this week, Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage. Brain shrinkage is a key marker of Alzheimer’s progression.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III programs, indicating that preservation of brain volume is associated with improved patient outcomes.The company said its trial data suggest patients with wild-type SIGMAR1 and COL24A1 genes may see greater clinical and structural benefits from blarcamesine.MRI biomarker analysis showed a strong and consistent link between reduced brain atrophy and improvements in cognition, daily activities, and overall clinical outcomes, Anavex said.<a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 21% year-to-date and 71% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 43% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-lockheed-martin-quadruple-precision-strike-missiles-production-iran-war/cZ3YFRyRIS9">Lockheed Martin To Quadruple Precision Strike Missile Output After First Combat Use In Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Anavex Life Sciences Corp

iShares Biotechnology ETF

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.33
Prev Close	$1.36
Open	$1.34
Dividend Yield	0.00%
50-Day Moving Average	$2.34
Beta	1.58
Avg. Volume	805,423.94
PE Ratio	-8.77

52-Week High	$8.79
52-Week Low	$1.14
Market Capitalization	$123.29M
EPS (Annual)	-$0.5438
Price to Book	1.10
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVXL Fundamentals